Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

WHY cancer researchers CHOOSE US


Why Our Antibodies Are the Preferred Choice for Cancer Research

Revolutionizing Cancer Research through Innovative Antibody Solutions

Welcome to NeoBiotechnologies, the leading biotechnology company dedicated to advancing immuno-oncology research and transforming cancer treatment. Our cutting-edge antibodies have redefined the landscape of cancer therapeutics, offering breakthrough solutions that empower researchers and clinicians in their quest to conquer cancer.

NeoBiotechnologies is at the forefront of innovation in the field of immuno-oncology, offering a comprehensive suite of antibodies that revolutionize cancer research and treatment. With unmatched specificity, superior immunomodulatory properties, and expanded therapeutic and diagnostic opportunities, our antibodies empower researchers and clinicians to push the boundaries of what is possible in the fight against cancer. Join us in our mission to transform our understanding of cancer and make a lasting difference in the lives of patients worldwide.

Discover the NeoBiotechnologies difference and explore why our antibodies are the preferred choice for cancer research.

Unparalleled Specificity and Targeting

At NeoBiotechnologies, we understand the importance of precise and targeted interventions in immuno-oncology research. Our antibodies are developed with unparalleled specificity, enabling them to selectively recognize and bind to cancer-specific markers. Our antibodies undergo multiple validation techniques, including innovative HuProtTM Protein Array Validation in which antibodies are tested for specificity against 21,000 full-length proteins on a single slide. With NeoBiotechnologies’ antibodies, researchers can confidently study cancer cells and unravel new insights into disease mechanisms and pathologists can be confident about the diagnoses they make.

Expanded Research Opportunities

NeoBiotechnologies’ extensive portfolio of over 5000 unique antibody products, available in over 15,000 formulations against over 1,000 human genes, offers researchers an expansive range of opportunities. Our antibodies are designed to target various types of cancer, including solid tumors and hematological malignancies. With NeoBiotechnologies’ antibodies, researchers can explore new avenues in precision medicine, tailoring therapies to individual patients and their unique cancer profiles.

Pioneering Research Collaborations

Collaboration is at the heart of scientific progress, and NeoBiotechnologies is committed to fostering partnerships with esteemed researchers and institutions worldwide. By actively engaging in collaborative research projects, we ensure that our antibodies are rigorously tested and optimized, pushing the boundaries of cancer research and treatment. Together, we can unlock new breakthroughs, accelerate discoveries, and assist pathologists in making a meaningful impact on patients’ lives.


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.